

TromboGene™

Genetic Study of Hereditary Thrombophilia

PANEL EVALUATION

Factor V Leiden
Factor II
MTHFR
and others.



HEARTGENETICS
GENETICS & BIOTECHNOLOGY

Know more:
(+351) 231 410 896

www.heartgenetics.com

Genetic study through a comprehensive and scientifically validated genetic panel with relevant clinical utility. TromboGene™ is performed using single targeted variant analysis through the highly accurate and innovative iPLEX® MassARRAY® system. TromboGene™ provides more integrative and accessible clinical knowledge through genetics.

F2 Coagulation factor II (prothrombin)
FV Coagulation factor V (proaccelerin, labile factor)
PROCR Protein C receptor, endothelial
PROS1 Protein S (alpha)
MTHFR Methylene tetrahydrofolate reductase (NAD(P)H)

PAI-1 Serpin Peptidase Inhibitor, Clade E (Nexin, Plasminogen Activator Inhibitor Type 1)
F13A1 Coagulation factor XIII, A1 polypeptide
FGB Fibrinogen beta chain
GP1BA Glycoprotein Ib (platelet), alpha polypeptide
SERPINC1 Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Co-sponsored by

CENTRO 2020

PORTUGAL 2020



UNIAO EUROPEIA
Fundo Europeu de Desenvolvimento Regional



New patient-centered genetic tests

Genetic testing for preventive and personalised medicine
Genotyping by DNA Microchip, iPLEX® MassARRAY®

■ Hypertrophic Cardiomyopathy, HCMscreening™

Dysfunction of the cardiac contraction mechanism
53 Genes: MYH7, MYBPC3, TNNT2, TNNI3, among others.

■ Arterial Hypertension, DNArterial®

Worldwide Innovation

Pathophysiology of high blood pressure
37 Genes: ACE, AGT, REN among others.

Includes a genetic risk classifier and pharmacogenetic analysis

■ Familial Hypercholesterolemia, LipoGene™

Severe elevation of serum cholesterol
6 Genes: LDLR, PCSK9, APOB and APOE among others.

Pharmacogenetics - Adverse drug response

In accordance with the recommendations from the US Food and Drug Administration and The Clinical Pharmacogenetics Implementation Consortium.

■ Warfarin pharmacogenetics (WRF)

2 Genes: CYP2C9 and VKORC1

■ Clopidogrel pharmacogenetics (CLP)

1 Gene: CYP2C19

■ Simvastatin pharmacogenetics (SVT)

1 Gene: SLCO1B1



WORLD
HEALTH
SUMMIT

HeartGenetics was selected as one of world's ten most innovative healthcare startups during the World Health Summit 2015.

Accessible, pathology-focused and informative genetic tests. Personalised support to clinic diagnosis and decision making.

HeartGenetics, Genetics & Biotechnology SA
Biocant Park, Núcleo 04, Lote 4A
3060-197 Cantanhede
Portugal

contact@heartgenetics.com

+351 231 410 896



HEARTGENETICS
GENETICS & BIOTECHNOLOGY

ISO 9001
BUREAU VERITAS
Certification



UK NEQAS

FOUNDATION
everis
WINNER

Informative flyer for medical doctors

The recommendations from the European Society of Cardiology for Cardiovascular Prevention (2003) group cardiovascular risk factors into 1) lifestyle, 2) modifiable biochemical and physiological traits, and 3) unmodifiable traits such as age, gender and familial history or genetic makeup.